Explore 3 Stock Ideas & Industry Insights Download Free Report

Ascletis Pharma Inc

Company price
0.5622 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
5000
Market Cap
2424.63M

Momentum Score

…

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.56
Low
0.72
High
52 Week Price Range
0.81
Low
2.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Ascletis Pharma Inc is a China-based biopharmaceutical company developing and commercializing therapeutic candidates, primarily in liver disease and oncology, and is quoted on the U.S. OTC Pink market. Long-term growth drivers may include clinical pipeline progress, regulatory approvals, and strategic partnerships that could support commercialization and geographic expansion. Investors may find exposure to specialty therapies in underserved indications attractive.
Key investment risks are significant clinical and regulatory uncertainty, intense competition from larger pharmaceutical companies, funding and liquidity constraints tied to its Pink listing, and limited public disclosures that reduce transparency.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.56
Dividend Yield
-
Revenue TTM
2.03M
Revenue Per Share
0.00
Gross Profit TTM
0.53M
Debt / Equity
0.00
ROE
-18.45%
Net Debt
-1439.08M
ROCE
-24.29%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -350.10M -300.94M -144.72M -314.84M -199.02M
Net income -350.59M -300.94M -144.72M -314.84M -199.02M
Selling general administrative - 101.74M 62.58M 15.43M 16.49M
Selling and marketing expenses - - 0.39M 16.98M 20.87M
Gross profit -16.65M 0.73M 25.99M -24.69M 39.17M
Reconciled depreciation - 20.45M 18.48M 30.19M 29.55M
Ebit -471.27M -404.63M -144.57M -262.82M -195.90M
Ebitda -454.11M -390.45M -126.09M -232.63M -166.35M
Depreciation and amortization 17.16M 14.18M 18.48M 30.19M 29.55M
Operating income -471.27M -295.42M -300.21M -262.82M -195.90M
Other operating expenses 473.25M 296.70M 356.80M 393.72M 260.96M
Interest expense 0.16M 0.24M 0.14M 0.16M 0.12M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 92.24M 99.28M 44.16M 22.51M
Net interest income - 91.99M 99.13M 44.01M 22.38M
Income tax expense -0.49M - 95.40M - -
Total revenue 1.98M 1.28M 56.60M 54.09M 76.88M
Total operating expenses 454.63M 296.15M 326.20M 314.94M 223.26M
Cost of revenue 18.62M 0.55M 30.61M 78.78M 37.70M
Total other income expense net 121.17M -5.52M 155.49M -52.03M -3.12M
Net income from continuing ops - -300.94M -144.72M -314.84M -199.02M
Net income applicable to common shares - - - -314.84M -199.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2067.57M 2124.57M 2491.01M 2657.04M 2829.96M
Intangible assets - 12.12M 26.32M 16.56M 78.21M
Other current assets 4.75M 13.74M 19.43M 8.12M 2.34M
Total liab 129.94M 158.41M 148.94M 117.16M 100.89M
Total stockholder equity 1935.24M 1966.16M 2342.07M 2539.89M 2729.07M
Deferred long term liab - - - 0.70M 0.42M
Other current liab 123.44M 142.70M 132.60M 102.64M 88.35M
Common stock 0.68M 0.69M 0.73M 0.74M 0.75M
Capital stock - 0.69M 0.73M 0.74M 0.75M
Retained earnings - -1475.34M -1174.40M -1029.69M -714.85M
Other liab - - - 7.15M 8.73M
Other assets - - - 1.91M 0.83M
Cash 1444.24M 865.73M 330.12M 2470.83M 2495.50M
Total current liabilities 127.66M 153.05M 140.68M 108.19M 90.97M
Current deferred revenue - - -5.71M - -
Net debt -1439.08M -858.10M -321.70M -2466.60M -2492.75M
Short term debt 2.87M 6.25M 5.71M 2.42M 1.57M
Short long term debt total 5.16M 7.63M 8.42M 4.24M 2.75M
Other stockholder equity 1934.56M 2693.26M 2791.18M 3568.83M 2728.33M
Property plant equipment - - - 71.83M 77.51M
Total current assets 1921.69M 1970.78M 2332.76M 2544.73M 2631.55M
Net tangible assets - - - 2523.33M 2650.86M
Short term investments 457.59M 1081.80M 1969.29M 11.20M 5.20M
Net receivables 13.23M 5.14M 4.00M 23.87M 67.39M
Inventory 1.87M 4.37M 6.07M 20.52M 56.23M
Accounts payable 1.34M 0.03M 0.65M 3.13M 1.05M
Accumulated other comprehensive income - 747.55M 724.56M - -
Non currrent assets other 0.46M 1081.88M 1969.92M 11.90M 5.62M
Non current assets total 145.88M 153.79M 158.25M 112.32M 198.41M
Capital lease obligations - 7.63M 8.42M 4.24M 2.75M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 978.91M 149.84M -1297.39M -269.78M 170.96M
Change to liabilities - - 0.49M -2.48M -7.44M
Total cashflows from investing activities 978.91M 149.84M -1297.39M -274.49M 132.30M
Net borrowings - - -2.22M -2.28M -1.93M
Total cash from financing activities -103.51M -81.50M -1.42M -31.10M -21.67M
Change to operating activities - - 16.41M 24.37M -6.67M
Net income -300.94M -144.72M -314.84M -199.02M -209.24M
Change in cash 534.21M -73.65M -1323.64M -483.09M -84.54M
Begin period cash flow 330.12M 403.77M 1727.41M 2210.50M 2295.04M
End period cash flow 864.33M 330.12M 403.77M 1727.41M 2210.50M
Total cash from operating activities -341.58M -144.16M -142.45M -146.93M -84.91M
Issuance of capital stock - 0.00M 0.96M - -
Depreciation 20.45M 18.48M 30.19M 29.55M 27.16M
Other cashflows from investing activities 121.09M -12.82M 3.32M 2.48M 0.29M
Change to inventory -3.60M -8.05M -12.84M -5.07M -18.37M
Change to account receivables 5.28M 18.44M 29.74M -26.99M 42.98M
Sale purchase of stock -98.53M -78.96M 0.00M -28.69M -19.60M
Other cashflows from financing activities -0.24M -0.14M -2.38M -2.41M -2.07M
Change to netincome - - 108.08M 32.29M 86.22M
Capital expenditures 2.15M 19.16M 14.40M 7.20M 38.96M
Change in working capital 13.79M 38.53M 33.81M -10.18M 10.43M
Stock based compensation 3.00M 1.33M 3.19M 7.13M 4.61M
Other non cash items -77.89M -57.78M 105.20M 25.59M 82.13M
Free cash flow -343.73M -163.32M -156.85M -154.13M -123.87M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ASCLF
Ascletis Pharma Inc
-
-%
0.56 - - 1195.58 7.81 7500.86 -0.13
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.

12/F, Building D, Hangzhou, China, 311200

86 571 8538 9730

208

Name Title Year Born
Dr. Jinzi Jason Wu Founder, Chairman & CEO 1963
Dr. Handan He Ph.D. Chief Scientific Officer 1962
Ms. Hejingdao Wu Sr. VP of Operations & Exec. Director 1974
Ms. Yuemei Yan Sr. VP of Clinical Devel. Operations 1970
Dr. Kristjan Sigurdur Gudmundsson Sr. Consultant & Head of Discovery 1968
Dr. George Zhengzhi Hill Sr. Consultant & Chief Medical Advisor 1951
Mr. John P. Gargiulo M.B.A. Chief Bus. Officer NA
Mr. Ming Fai Chung CPA Company Sec. NA
Dr. Jinzi Jason Wu Ph.D. Founder, Chairman & CEO 1964
Ms. Hejingdao Wu Senior VP of Operations & Executive Director 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…